County recommends operator to take over Dayton's largest homeless shelter
The county has announced its recommendation to take over the operations of Dayton's largest homeless shelter.
[DOWNLOAD: Free WHIO-TV News app for alerts as news breaks]
Homefull, Inc. has been recommended by Montgomery County to take over the Gettysburg Gateway Shelter for Men.
This comes after St. Vincent de Paul announced in November that it would stop operating the shelter at the end of June.
St. Vincent de Paul opened the Gettysburg shelter for men 15 years ago.
TRENDING STORIES:
Memorial service announced for local college student who died from gunshot wound
Ohio fugitive arrested for 29th time after police chase
Can you help? Police searching for man accused of stealing almost $1700 worth of clothing
The decision was financial, Michael Vanderburgh, executive director, St. Vincent de Paul Society said.
'We've experienced both great inflationary pressures and the disappearance of extraordinary government funding to help us through the pandemic,' Vanderburgh previously told News Center 7.
The shelter will continue to provide shelter without barriers or preconditions, according to a media release.
The county said it will collaborate with St. Vincent de Paul and Homefull, Inc. to ensure a smooth transition. negotiations
Once contract negotiations are completed, a purchase agreement will be presented for approval, outlining costs and a start date, the county said.
We will continue to follow this story.
[SIGN UP: WHIO-TV Daily Headlines Newsletter]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
37 minutes ago
- Business Wire
Debiopharm and Alkyon Therapeutics Announce Research Collaboration to Advance the Next Generation of Radioligand Therapies
MARTIGNY, Switzerland & LAUSANNE, Switzerland & SAN DIEGO--(BUSINESS WIRE)--Debiopharm ( a privately-owned Swiss biopharmaceutical company committed to establishing tomorrow's standard of care to cure cancer and infectious diseases and Alkyon Therapeutics, Inc., a biotechnology company pioneering precision-targeted therapies, today announced the signing of a co-research agreement to evaluate the feasibility of developing targeted radioligand therapies (RLTs) using Debiopharm's proprietary AbYlink™ conjugation technology for Alkyon's modular antibody platform directed against undisclosed tumor-associated antigens. This collaboration marks a promising step toward a new generation of RLTs designed to deliver potent radiation targeted directly to cancer cells while minimizing damage to healthy tissues. By leveraging the unique strengths of both platforms, the goal is to create more effective, better-tolerated cancer treatments that improve patient quality of life and expand therapeutic options for difficult-to-treat tumors. AbYLink™ technology enables regio-selective lysine conjugation, ensuring the radioligand avoids the target binding site and facilitating streamlined, consistent manufacturing. 'We're intrigued to explore the potential of applying AbYlink™ conjugation technology to the radio-oncology field,' expressed Frederic Levy, Chief Scientific Officer, Debiopharm. 'Leveraging our innovative conjugation platform with Alkyon's engineered antibody scaffolds could open new possibilities for next-generation radiopharmaceuticals with enhanced precision and therapeutic impact.' 'This collaboration reflects our shared commitment to expanding the potential of radioligand therapies,' said Benjamin Titz, Co-Founder and CEO of Alkyon Therapeutics. 'By applying AbYlink™ to our specialized antibody scaffolds and targeting strategies tailored to the unique architecture of solid tumors, we aim to unlock new therapeutic possibilities and advance care for patients with difficult-to-treat solid tumors.' About AbYlink™ AbYlink™ is a versatile and rapid regio-selective chemical conjugation technology for use in preparing diagnostic or therapeutic conjugates. This one-step method results in stable conjugation at defined and invariable sites on the Fc domain of an antibody or the like, with no impact on antigen-binding regions. It enables a seamless and reproducible conjugation of payloads (e.g., a chelator for radiolabeling, a fluorescent dye or a drug) to antibodies or ADCs. The universal applicability of the technology has been demonstrated for various antibody isotypes and payloads. About Alkyon Therapeutics, Inc. Alkyon Therapeutics, Inc. (AlkyonTx™) is a biotechnology company developing next-generation radioligand therapies (RLTs) for solid tumors. By combining precision-engineered antibodies with advanced radiochemistry and dosimetry technologies, Alkyon aims to overcome barriers such as immune exclusion and drug resistance in difficult-to-treat cancers. Its modular platform supports monotherapies, bispecifics, and rational combinations designed to enable differentiated clinical benefit and scalable product development. Debiopharm's commitment to patients Debiopharm aims to develop innovative therapies that target high unmet medical needs primarily in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then hand stewardship to large pharmaceutical commercialization partners to maximize patient access globally. For more information, please visit
Yahoo
40 minutes ago
- Yahoo
Should You Think About Buying Mitek Systems, Inc. (NASDAQ:MITK) Now?
While Mitek Systems, Inc. (NASDAQ:MITK) might not have the largest market cap around , it received a lot of attention from a substantial price increase on the NASDAQCM over the last few months. The recent rally in share prices has nudged the company in the right direction, though it still falls short of its yearly peak. With many analysts covering the stock, we may expect any price-sensitive announcements have already been factored into the stock's share price. However, what if the stock is still a bargain? Let's take a look at Mitek Systems's outlook and value based on the most recent financial data to see if the opportunity still exists. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Great news for investors – Mitek Systems is still trading at a fairly cheap price. Our valuation model shows that the intrinsic value for the stock is $16.49, but it is currently trading at US$10.10 on the share market, meaning that there is still an opportunity to buy now. Although, there may be another chance to buy again in the future. This is because Mitek Systems's beta (a measure of share price volatility) is high, meaning its price movements will be exaggerated relative to the rest of the market. If the market is bearish, the company's shares will likely fall by more than the rest of the market, providing a prime buying opportunity. View our latest analysis for Mitek Systems Future outlook is an important aspect when you're looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Although value investors would argue that it's the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. However, with an extremely negative double-digit change in profit expected next year, near-term growth is certainly not a driver of a buy decision. It seems like high uncertainty is on the cards for Mitek Systems, at least in the near future. Are you a shareholder? Although MITK is currently undervalued, the adverse prospect of negative growth brings about some degree of risk. We recommend you think about whether you want to increase your portfolio exposure to MITK, or whether diversifying into another stock may be a better move for your total risk and return. Are you a potential investor? If you've been keeping tabs on MITK for some time, but hesitant on making the leap, we recommend you research further into the stock. Given its current undervaluation, now is a great time to make a decision. But keep in mind the risks that come with negative growth prospects in the future. So while earnings quality is important, it's equally important to consider the risks facing Mitek Systems at this point in time. At Simply Wall St, we found 1 warning sign for Mitek Systems and we think they deserve your attention. If you are no longer interested in Mitek Systems, you can use our free platform to see our list of over 50 other stocks with a high growth potential. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Business Wire
41 minutes ago
- Business Wire
Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026
CARLSBAD, Calif.--(BUSINESS WIRE)-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Richard Geary, Ph.D., executive vice president and chief development officer, will retire effective January 2026 and that Holly Kordasiewicz, Ph.D., currently senior vice president, neurology, will succeed him in the role. 'Richard has made tremendous contributions to Ionis over his 30-year tenure during which he spearheaded dozens of development programs and brought six innovative medicines through regulatory approvals, including TRYNGOLZA, our first independent commercial medicine. We thank him for his leadership and unwavering dedication to patients in need,' said Brett P. Monia, Ph.D., chief executive officer, Ionis. 'Holly is a deeply respected and innovative leader who will champion our vision to bring a steady cadence of transformational medicines to people in need and support Ionis' continued growth as a fully integrated biotechnology company. Her broad experience across research and development, strong operational and management skills, and deep neurology expertise, position Holly to successfully guide our portfolio, which includes eight wholly owned neurology medicines in clinical development.' Dr. Kordasiewicz has 20 years of experience in research and development and joined Ionis in 2011. An expert in neurology drug development, she currently oversees Ionis' industry-leading neurology program, including medicines for Alexander disease, Angelman syndrome, Alzheimer's disease, prion disease and multiple system atrophy. Dr. Kordasiewicz also played an integral role in the discovery and development of our Biogen-partnered programs QALSODY ® (tofersen) for a genetic form of amyotrophic lateral sclerosis and IONIS-MAPT Rx (BIIB080), a promising Alzheimer's disease medicine in Phase 2 development. Dr. Kordasiewicz holds a B.A. from SUNY-Geneseo and a Ph.D. in Neuroscience from the University of Minnesota. She completed postdoctoral work at the University of Minnesota and the University of California San Diego. Dr. Geary joined Ionis in 1995 and has been involved in nearly every aspect of discovery and development. Under Dr. Geary's leadership, Ionis submitted more than 50 investigational new drug applications to regulatory agencies and achieved six FDA and EU approvals, including TRYNGOLZA ® (olezarsen). Dr. Geary will serve as a strategic consultant to Ionis throughout 2026 to support a seamless transition. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has six marketed medicines and a leading pipeline in neurology, cardiology and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit and follow us on X (Twitter), LinkedIn and Instagram. Ionis Forward-looking Statements This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of our commercial medicines, additional medicines in development and technologies. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2024, and most recent Form 10-Q, which are on file with the Securities and Exchange Commission. Copies of these and other documents are available from the Company. In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our" and "us" all refer to Ionis Pharmaceuticals and its subsidiaries. Ionis Pharmaceuticals ® and TRYNGOLZA ® are trademarks of Ionis Pharmaceuticals, Inc. QALSODY ® is a registered trademark of Biogen.
